Spotlight on rare NMOSD: Chord launches with $16m Series A round
Geneva-based Chord Therapeutics has launched with $16m Series A funding from Omega Funds. As a result of the round, Omega...
-
Endo InternationalMergers & Acquisitions$540M
-
Eli LillyMergers & Acquisitions$135M
-
Boehringer IngelheimPartnershipUndisclosed
-
RhizenPartnership$149.5M
-
PfizerPartnership$200M
-
PfizerPartnershipUndisclosed
-
AstraZenecaPartnership$486M
-
Takeda PharmaceuticalLicensing Agreement$1.04BN
-
Gilead SciencesPartnershipUndisclosed
-
Roche, EnterpriseMergers & Acquisitions$96.7M
-
Piramal, Carlyle GroupMergers & Acquisitions$480M
-
Bristol Myers SquibbMergers & Acquisitions$13.1BN
-
BridgeBioMergers & Acquisitions$175M
-
Covis GroupMergers & Acquisitions$647M
-
Eisai; SeikagakuPartnershipUndisclosed
-
FujifilmPartnershipUndisclosed
-
Koligo, OrgenesisMergers & Acquisitions$15M
-
CStoneMergers & Acquisitions$200M
-
XtalPiCapital Raising$318.8M
-
InventisBioCapital Raising$147M
-
Monte Rosa TherapeuticsCapital Raising$96M
-
PermiraMergers & Acquisitions$1.8BN
-
GenentechPartnershipUndisclosed
-
Bausch HealthLicensing Agreement$50M
-
RocheMergers & Acquisitions$449M
-
Palleon PharmaceuticalsCapital Raising$100M
-
AstraZenecaLicensing AgreementUndisclosed
-
ModernaLicensing Agreement$455M
-
Ansa BiotechnologiesMergers & Acquisitions$7.9M
-
MerckPartnership$4.2BN
-
![PP2A Rappta]()
Targeting PP2A to tackle cancers: Rappta closes €9m Series A round
-
![Phenomic tumour stroma]()
Targeting the tumour stroma: Phenomic AI launches with $6m seed financing
-
![]()
Breaking the taboo: disrupting the fertility sector
-
![Galecto fibrosis]()
Tackling fibrosis: Galecto raises $64m in equity financing
-
![Libra neurodegeneration]()
Innovation in neurodegeneration: Libra launches with $29m Series A
-
![SporeGen Covid-19]()
Beyond vaccines: SporeGen, Destiny partner on nasal spray to prevent Covid-19
Submit a deal
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
DEALS ANALYSIS
Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A
Systemic amyloidosis-focused Attralus has launched after raising $25m in a Series A fundraising round led by venBio Partners.
Next-gen gene editing: Graphite Bio launches with $45m funding
San Francisco-based Graphite Bio has launched after raising $45m in a Series A round. Graphite centres around its next-generation gene editing platform that achieves “a chief aim of gene editing...
Treating lysosomal storage disorders: Gain and Sumitomo Dainippon enter partnership
US-based Gain Therapeutics has signed a research partnership with Japan-headquartered Sumitomo Dainippon Pharma, leveraging the former’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to target previously undruggable allosteric binding sites....
Advancing next-gen CD47 antibodies: AbbVie and I-Mab sign $1.94bn partnership
Shanghai-headquartered biopharma I-Mab has signed a partnership with pharma giant AbbVie. The deal centres around further developing and commercialising I-Mab’s novel cluster of differentiation 47 (CD47) monoclonal antibody lemzoparlimab for...
Takeda bets on Engitix’s ECM drug discovery platform for liver fibrosis
London-headquartered Engitix is partnering with pharma giant Takeda to discover and develop novel therapies for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).
Powering biologics development with spirulina: Lumen closes $16m Series B
Seattle-based biologics developer Lumen Bioscience has raised $16m in a Series B financing round. The round was co-led by WestRiver Management and Bioeconomy Capital – the former is a new...
Protein misfolding and neurodegeneration: Yumanity and Proteostasis merger
Two Boston-based companies, Yumanity Therapeutics and Proteostasis Therapeutics, have signed a merger agreement. As a result of this merger, which is expected to close in the fourth quarter of 2020,...
Treating food allergies: Nestlé Health Science’s $2.6bn acquisition of Aimmune
Nestlé’s nutritional science brand Nestlé Health Science (NHSc) is to acquire California-based Aimmune Therapeutics. The acquisition is priced at $34.50 per share in cash, which represents $2.6bn and a 174%...
Promise of TROP2 ADCs: AstraZeneca, Daiichi Sankyo’s $6bn collaboration
Anglo-Swedish pharma giant AstraZeneca has entered into a global development and commercialisation agreement with Tokyo-headquartered Daiichi Sankyo for the latter’s TROP2 antibody drug conjugate (ADC) DS-1062.
Advancing AAV gene therapy: Forge closes $40m Series A
Gene therapy specialist Forge Biologics has raised $40m in Series A round. This fundraising was led by early stage-focused Perceptive Xontogeny Venture Fund (PXV Fund); as a result, the fund’s...